ArticleMediators of inflammation2026
Secretome From Human Micro-Fragmented Adipose Tissue Affects In Vitro Monocytes/Macrophages Inflammatory Activity by ICAM-1 Expression.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Secretome From Human Micro-Fragmented Adipose Tissue Affects In Vitro Monocytes/Macrophages Inflammatory Activity by ICAM-1 Expression.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Micro-fragmented adipose tissue (MFAT) is regarded as one of the simplest and most practical biological preparations for clinical applications in tissue regenerative medicine. The clinical effectiveness of MFAT is attributed to its content of cells and growth factors that facilitate tissue regeneration. In this study, we investigated the biological activity of the secretome derived from cultured MFAT. Our primary focus was on its ability to influence the production of two inflammatory cytokines, RANTES (Regulated and Normal T Cell Expressed and Secreted) and MCP-1 (Monocyte Chemoattractant Protein-1), using ELISA assays, as well as its impact on the expression of Cell Adhesion Molecules (CAMs) on U-937 macrophages via flow cytometry. We also explored the potential of the MFAT secretome to affect the proliferation of both normal and cancer cells. Our results showed that the MFAT secretome inhibited the production of MCP-1 and RANTES, significantly reduced the expression of ICAM-1 (Intercellular Adhesion Molecule 1) on U-937 macrophages, and had no impact on the proliferation of normal or cancer cells. These findings suggest that the MFAT secretome is relatively safe and exhibits anti-inflammatory properties, supporting the idea that its clinical effectiveness in treating joint inflammation may, in part, be due to its paracrine effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.